Has This Hot Med Tech Market Frozen Over?

Growth opportunities in health care are all about innovation, and few new, growing markets are heating up as much as renal denervation in medical tech. Renal denervation, a treatment for hypertension, could be a sleeper market to watch: the Millennium Research Group estimates that this medical device market could see revenue of up to $2.9 billion annually by 2021, hardly chump change for top leaders in the device industry.

Yet no growth market is immune to setbacks. Medtronic (NYSE: MDT  ) , one of the early leaders in developing renal denervation solutions with its Symplicity device, stumbled recently in clinical trials over its device's efficacy. U.S. regulatory approval for the Symplicity now looks far off in the future as the company rebounds from this device, and while Medtronic vows to keep the device on schedule, it's no doubt left investors disappointed.

But is Medtronic's setback a stumbling block for the renal denervation push in med tech, or is it just a window of opportunity for other hard-charging rivals in this space, such as St. Jude Medical (NYSE: STJ  ) ? In the video below, Motley Fool contributor Dan Carroll takes you through all you need to know about the renal denervation market's potential -- and which companies and stocks are the early leaders to reap big rewards down the road.

Can these two innovative names revolutionize your portfolio's potential?
Innovation's the name of the game in health care. The best way to play the health care space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2799265, ~/Articles/ArticleHandler.aspx, 11/22/2014 4:39:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 18 hours ago Sponsored by:
DOW 17,810.06 91.06 0.51%
S&P 500 2,063.50 10.75 0.52%
NASD 4,712.97 11.10 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/21/2014 4:04 PM
MDT $72.49 Up +0.41 +0.57%
Medtronic CAPS Rating: *****
STJ $66.80 Up +2.53 +3.94%
St. Jude Medical,… CAPS Rating: *****
BSX $12.94 Down -0.01 -0.08%
Boston Scientific… CAPS Rating: ***
COV $98.44 Up +0.53 +0.54%
Covidien CAPS Rating: *****

Advertisement